HTX has added Russia to its list of prohibited jurisdictions, restricting access to its services for individuals living in or physically present in Russia, as well as companies registered or primarily operating there. This move allows HTX to suspend withdrawals, restrict service access, or close accounts of affected users. Other exchanges like Bitget and MEXC have taken similar steps recently, reflecting growing regulatory and geopolitical pressures on crypto platforms serving Russian users.
The story about HTX adding Russia to its barred jurisdictions is provided here with market context from Pluang's cryptocurrency data. For readers following major cryptocurrencies, breadth shows 5 rose and 43 fell today. Notable movers include EOS at Rp12.649 with a +8.13% change, BAT at Rp2.887 with -8.03%, and EGLD at Rp60.257 with -7.67%. This data is as of Oct 24, 2026 21:01 WIB.
The Royal Canadian Legion has launched its 2026 National Poppy Campaign introducing a new contactless donation method using smartphones, supported by BMO and Toucan Giving technology. This innovation allows volunteers to collect donations via debit, ...
XBiotech Inc. announced the election of Jan-Paul Simard as Co-Chief Executive Officer alongside current CEO Dr. Sushma Shivaswamy, effective October 23, 2026. This leadership change aims to leverage their complementary skills and scientific expertise...
XBiotech Inc. announced the appointment of Sushma Shivaswamy and Jan-Paul Simard as co-chief executive officers, effective October 23, 2026. Shivaswamy, with 17 years at the company, has led scientific operations and was interim CEO since December 20...
Genmab and Incyte announced a Phase 1/2 clinical trial to test a combination of petosemtamab, INCB161734, and standard chemotherapy as a first-line treatment for metastatic colorectal cancer with the KRAS G12D mutation. This mutation is common and li...
Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3), used with radiotherapy and immune checkpoint inhibitors, in 24 heavily pretreated advanced melanoma patients resistant to anti-PD-1 therapies. The treatment showed a 41.7% obj...
